SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2023 Earnings Conference Call March 5, 2024 8:00 AM ET

Company Participants

Kellen Sanger - Head, Strategy & Investor Relations

Jurgi Camblong - Co-Founder & Chief Executive Officer

Ross Muken - Chief Executive Officer & Chief Operating Officer

Conference Call Participants

Dan Brennan - TD Cowen

Tejas Savant - Morgan Stanley

Conor McNamara - RBC Capital Markets

Operator

Good morning. My name is Drew, and I will be your conference operator today. At this time, I would like to welcome everyone to the SOPHiA GENETICS' Fourth Quarter and Full Year 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Kellen Sanger, SOPHiA GENETICS' Head of Strategy and Investor Relations. You may begin.

Kellen Sanger

Thank you, and good morning, everyone. Welcome to the SOPHiA GENETICS' fourth quarter and full year 2023 earnings conference call.

Joining me today to discuss our results are Dr. Jurgi Camblong, our Co-Founder and Chief Executive Officer, and Ross Muken, our Chief Financial Officer and Chief Operating Officer.

I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties and factors that could cause results to differ appears in the press release SOPHiA GENETICS issued today and in the documents and reports filed by SOPHiA GENETICS from time to time with the Securities and Exchange Commission.

During this call, we will present both IFRS and non-IFRS financial measures. A reconciliation of IFRS to non-IFRS measures is included in today's earnings press release, which is available on our website.

With that, I will now turn the call over to Jurgi.

Jurgi Camblong

Thanks, Kellen, and good morning, everyone.

During today's call, I will start with an overview of our progress in 2023, followed by a quick look at our performance in Q4. Next, I will highlight our key priorities for 2024. Then, Ross will provide a more detailed look at our financial results, business trends and guidance for the upcoming year.

Before I get started, I want to take a momentum to reflect on some of the trends we saw in healthcare in 2023 and also more broadly across industry. In many ways, 2023 was the year of AI. It was the first time that the general public gained access to powerful AI models and learn what they can do. As the Co-founder and leader of an AI-driven precision medicine company who has been working on building AI in healthcare since SOPHiA GENETICS' inception in 2011, this moment has been a fulfilling experience for me.